Three-dimensional structures of PDE4D in complex with roliprams and implication on inhibitor selectivity (Q27641624)

1

0 references

Huanchen Wang

2

0 references

Yingjie Sun

3

0 references

Hwa-Young Kim

4

0 references

Yudong Liu

Molecular diversity of cyclic AMP signalling

5

0 references

publication date

July 2003

0 references

published in

Structure

0 references

volume

11

0 references

issue

7

0 references

page(s)

865-73

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0969-2126%2803%2900123-0

7 January 2021

Identification of inhibitor specificity determinants in a mammalian phosphodiesterase

1 reference

https://api.crossref.org/works/10.1016%2FS0969-2126%2803%2900123-0

7 January 2021

Association of the anti-inflammatory activity of phosphodiesterase 4 (PDE4) inhibitors with either inhibition of PDE4 catalytic activity or competition for [3H]rolipram binding

1 reference

https://api.crossref.org/works/10.1016%2FS0969-2126%2803%2900123-0

7 January 2021

New phosphodiesterase inhibitors as therapeutics for the treatment of chronic lung disease

1 reference

https://api.crossref.org/works/10.1016%2FS0969-2126%2803%2900123-0

7 January 2021

Is phosphodiesterase inhibition a new mechanism of antidepressant action? A double blind double-dummy study between rolipram and desipramine in hospitalized major and/or endogenous depressives

1 reference

https://api.crossref.org/works/10.1016%2FS0969-2126%2803%2900123-0

7 January 2021

Crystallography & NMR System: A New Software Suite for Macromolecular Structure Determination

1 reference

https://api.crossref.org/works/10.1016%2FS0969-2126%2803%2900123-0

7 January 2021

Cyclic GMP phosphodiesterase-5: target of sildenafil

1 reference

https://api.crossref.org/works/10.1016%2FS0969-2126%2803%2900123-0

7 January 2021

Molecular docking of competitive phosphodiesterase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0969-2126%2803%2900123-0

7 January 2021

Phosphodiesterase 4 inhibitors and the treatment of asthma: where are we now and where do we go from here?

1 reference

https://api.crossref.org/works/10.1016%2FS0969-2126%2803%2900123-0

7 January 2021

Adaptation in cyclic AMP signalling processes: A central role for cyclic AMP phosphodiesterases

1 reference

https://api.crossref.org/works/10.1016%2FS0969-2126%2803%2900123-0

7 January 2021

Tailoring cAMP-signalling responses through isoform multiplicity

1 reference

https://api.crossref.org/works/10.1016%2FS0969-2126%2803%2900123-0

7 January 2021

The next generation of PDE4 inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0969-2126%2803%2900123-0

7 January 2021

Improved methods for building protein models in electron density maps and the location of errors in these models

1 reference

https://api.crossref.org/works/10.1016%2FS0969-2126%2803%2900123-0

7 January 2021

Striking effect of hydroxamic acid substitution on the phosphodiesterase type 4 (PDE4) and TNF alpha inhibitory activity of two series of rolipram analogues: implications for a new active site model of PDE4

1 reference

https://api.crossref.org/works/10.1016%2FS0969-2126%2803%2900123-0

7 January 2021

Conformational difference between PDE4 apoenzyme and holoenzyme

1 reference

https://api.crossref.org/works/10.1016%2FS0969-2126%2803%2900123-0

7 January 2021

Purification and characterization of the human PDE4A catalytic domain (PDE4A330-723) expressed in Sf9 cells

1 reference

https://api.crossref.org/works/10.1016%2FS0969-2126%2803%2900123-0

7 January 2021

Crystal structure of phosphodiesterase 4D and inhibitor complex(1)

1 reference

https://api.crossref.org/works/10.1016%2FS0969-2126%2803%2900123-0

7 January 2021

Dissecting the cofactor-dependent and independent bindings of PDE4 inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0969-2126%2803%2900123-0

7 January 2021

Type III cGMP-inhibited cyclic nucleotide phosphodiesterases (PDE3 gene family)

1 reference

https://api.crossref.org/works/10.1016%2FS0969-2126%2803%2900123-0

7 January 2021

Cyclic nucleotide phosphodiesterases and their role in endocrine cell signaling.

1 reference

https://api.crossref.org/works/10.1016%2FS0969-2126%2803%2900123-0

7 January 2021

Subtypes of the type 4 cAMP phosphodiesterases: structure, regulation and selective inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0969-2126%2803%2900123-0

7 January 2021

[33] AMoRe: An automated molecular replacement program package

1 reference

https://api.crossref.org/works/10.1016%2FS0969-2126%2803%2900123-0

7 January 2021

Processing of X-ray diffraction data collected in oscillation mode

1 reference

https://api.crossref.org/works/10.1016%2FS0969-2126%2803%2900123-0

7 January 2021

Phosphodiesterase 4 inhibitors, structurally unrelated to rolipram, as promising agents for the treatment of asthma and other pathologies

1 reference

https://api.crossref.org/works/10.1016%2FS0969-2126%2803%2900123-0

7 January 2021

Cilostazol: treatment of intermittent claudication

1 reference

https://api.crossref.org/works/10.1016%2FS0969-2126%2803%2900123-0

7 January 2021

Identification of inhibitor binding sites of the cAMP-specific phosphodiesterase 4.

1 reference

https://api.crossref.org/works/10.1016%2FS0969-2126%2803%2900123-0

7 January 2021

Human recombinant phosphodiesterase 4B2B binds (R)-rolipram at a single site with two affinities

1 reference

https://api.crossref.org/works/10.1016%2FS0969-2126%2803%2900123-0

7 January 2021

Phosphodiesterase 5 inhibitors: current status and potential applications

1 reference

https://api.crossref.org/works/10.1016%2FS0969-2126%2803%2900123-0

7 January 2021

Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions

1 reference

https://api.crossref.org/works/10.1016%2FS0969-2126%2803%2900123-0

7 January 2021

Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0969-2126%2803%2900123-0

7 January 2021

Phosphodiesterase 4 inhibitors for the treatment of COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS0969-2126%2803%2900123-0

7 January 2021

Cyclic nucleotide phosphodiesterases: pharmacology, biochemistry and function

1 reference

https://api.crossref.org/works/10.1016%2FS0969-2126%2803%2900123-0

7 January 2021

Phosphodiesterase isozymes: molecular targets for novel antiasthma agents

1 reference

https://api.crossref.org/works/10.1016%2FS0969-2126%2803%2900123-0

7 January 2021

Atomic structure of PDE4: insights into phosphodiesterase mechanism and specificity

1 reference

https://api.crossref.org/works/10.1016%2FS0969-2126%2803%2900123-0

7 January 2021